Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials argenx SE Nasdaq

Equities

ARGX

US04016X1019

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-20 EDT 		5-day change 1st Jan Change
361.6 USD -1.16% Intraday chart for argenx SE +0.58% -4.95%
05-17 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
05-15 European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,141 11,400 16,291 19,269 20,293 19,886 - -
Enterprise Value (EV) 1 4,811 9,781 14,186 18,515 17,352 17,524 17,397 16,897
P/E ratio -34 x -20.8 x -43.8 x -28.3 x -72.1 x -121 x 124 x 36.2 x
Yield - - - - - - - -
Capitalization / Revenue 74.4 x 209 x 33.5 x 45.9 x 17.3 x 11.6 x 8.63 x 6.72 x
EV / Revenue 58.3 x 179 x 29.2 x 44.1 x 14.8 x 10.3 x 7.55 x 5.71 x
EV / EBITDA -27.3 x -23.6 x -45.7 x -31.9 x -59.8 x -76.7 x 72.3 x 22.2 x
EV / FCF 36.2 x -28.2 x -25.7 x -22.8 x -40.4 x -63.2 x 151 x 39.8 x
FCF Yield 2.76% -3.55% -3.9% -4.39% -2.47% -1.58% 0.66% 2.51%
Price to Book 5.84 x 8.44 x 7.1 x - 5.39 x 5.27 x 4.91 x 4.22 x
Nbr of stocks (in thousands) 42,762 47,108 51,668 55,324 59,079 59,431 - -
Reference price 2 143.6 242.0 315.3 348.3 343.5 334.6 334.6 334.6
Announcement Date 20-02-27 21-03-04 22-03-03 23-03-02 24-02-29 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 82.58 54.53 486.3 419.9 1,171 1,708 2,304 2,958
EBITDA 1 -176.4 -414.3 -310.4 -580.3 -290.2 -228.6 240.6 762
EBIT 1 -178.6 -417.8 -314.4 -679.3 -392.3 -250.7 92.72 604.5
Operating Margin -216.21% -766.07% -64.65% -161.78% -33.51% -14.68% 4.02% 20.44%
Earnings before Tax (EBT) 1 -158.2 -526.3 -360.4 -687.7 -281 -139.7 192.9 686.8
Net income 1 -163 -528.9 -368.1 -669.1 -272.3 -157.2 169.2 632.3
Net margin -197.33% -969.9% -75.69% -159.36% -23.26% -9.2% 7.34% 21.38%
EPS 2 -4.220 -11.65 -7.203 -12.31 -4.763 -2.769 2.699 9.244
Free Cash Flow 1 133 -347.3 -552.7 -813.6 -429.4 -277.4 115.2 424.4
FCF margin 161.02% -636.85% -113.66% -193.76% -36.67% -16.24% 5% 14.35%
FCF Conversion (EBITDA) - - - - - - 47.86% 55.7%
FCF Conversion (Net income) - - - - - - 68.08% 67.12%
Dividend per Share 2 - - - - - - - -
Announcement Date 20-02-27 21-03-04 22-03-03 23-03-02 24-02-29 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1
Net sales 1 31.28 6.131 40.42 - 29.8 84.08 145.5 171.7 309.9 207.8 253.8 461.4 320.3 385.7 699.3 383.8 403.8 783 438.8 480.2 887.9 500.7
EBITDA 1 - -182.1 -197.7 - -211.5 -170.3 -208 - - - - - - - - -70.62 -82.89 - -87.26 -70.66 - -
EBIT 1 -94.09 -183.8 -208.2 - -210.9 -172.3 -207.2 -107.9 -304.7 -93.84 -92.2 -185.9 -75.95 -127.9 -202.3 -86.93 -77.65 -169.8 -60.56 -38.59 -151.2 11.42
Operating Margin -300.74% -2,997.28% -515.01% - -707.52% -204.9% -142.43% -62.83% -98.32% -45.15% -36.33% -40.29% -23.71% -33.18% -28.93% -22.65% -19.23% -21.69% -13.8% -8.04% -17.03% 2.28%
Earnings before Tax (EBT) 1 -113.4 -199.2 -220.8 - -217.8 -214.2 -239.4 -38.89 -266.2 -68.9 -75.73 -144.5 -78.49 -56.47 -133.3 -69.18 -48.24 -64.05 -29.64 -11.23 -60.64 20.45
Net income 1 -117.8 -201.6 -214.4 -425 -215.1 -206 -233.5 -36.41 -258.1 -26.11 -85.22 -111.3 -68.47 -91.54 -158.6 -57.32 -51.32 -64.05 -32.32 -15.72 -60.64 26.93
Net margin -376.68% -3,288.02% -530.42% - -721.69% -245.06% -160.45% -21.2% -83.28% -12.57% -33.58% -24.12% -21.38% -23.73% -22.68% -14.93% -12.71% -8.18% -7.36% -3.27% -6.83% 5.38%
EPS 2 - -3.797 -4.291 - - -3.760 -4.231 -0.6601 - -0.4703 -1.526 - -1.178 -1.551 - -0.5995 -1.246 - -1.360 -0.7800 - -
Dividend per Share 2 - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 20-02-27 21-10-28 22-03-03 22-03-03 22-05-05 22-07-28 22-10-27 23-03-02 23-03-02 23-05-04 23-07-27 23-07-27 23-10-31 24-02-29 24-02-29 24-05-09 - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,329 1,619 2,105 754 2,942 2,362 2,488 2,988
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 133 -347 -553 -814 -429 -277 115 424
ROE (net income / shareholders' equity) -20.5% -43.8% -19.4% -26.5% -8.54% -5.05% 5.2% 16%
ROA (Net income/ Total Assets) -16.2% -32.1% -15.9% -23.7% -7.69% -2.85% 4.89% 13.8%
Assets 1 1,006 1,646 2,312 2,822 3,543 5,524 3,457 4,586
Book Value Per Share 2 24.60 28.70 44.40 - 63.70 63.50 68.20 79.30
Cash Flow per Share 2 - - -10.80 - -6.800 2.410 5.320 12.50
Capex 1 1.6 0.95 3.28 0.79 40.5 9.91 10.3 14.7
Capex / Sales 1.94% 1.74% 0.67% 0.19% 3.46% 0.58% 0.45% 0.5%
Announcement Date 20-02-27 21-03-04 22-03-03 23-03-02 24-02-29 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for argenx SE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
334.6 EUR
Average target price
432.9 EUR
Spread / Average Target
+29.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 106B
BIONTECH SE Stock BioNTech SE
-12.38% 21.87B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 12.42B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.50% 8.23B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. ARGX Stock
  5. Financials argenx SE
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW